Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.2K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.2K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.6K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.6K
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

1.2K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.2K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.3K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.3K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

688
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
688

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observer bias in medical evaluations: a critical pre-analytical factor impacting the quality of judicial evidence in forensic-toxicological casework.

International journal of legal medicine·2026
Same author

Impact of moderate alcohol consumption on visuo-motor skills in neurosurgical residents.

Scientific reports·2026
Same author

Direct alcohol biomarkers in blood samples of traffic offenders - correlation between blood alcohol concentration, ethyl glucuronide, and phosphatidylethanol.

International journal of legal medicine·2026
Same author

Gastric emptying times of high-fat, high-carbohydrate and high-protein standard meals using MRI examinations - a contribution to estimating the time since death.

International journal of legal medicine·2026
Same author

Pitfalls in body fluid identification - age independent DNA methylation markers for vaginal secretions and menstrual blood in sexual assaults.

International journal of legal medicine·2026
Same author

Quantitative and qualitative changes in substance-related administrative offences in road traffic during the SARS-CoV-2 pandemic in Munich.

PloS one·2025
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
12:00

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

Published on: November 19, 2014

13.4K

Perphenazine for schizophrenia.

Benno Hartung1, Stephanie Sampson, Stefan Leucht

  • 1Institute for Legal Medicine, University Hospital Düsseldorf, Moorenstr. 5, Düsseldorf, North Rhine Westphalia, Germany, 40225.

The Cochrane Database of Systematic Reviews
|March 10, 2015
PubMed
Summary
This summary is machine-generated.

Perphenazine, an older antipsychotic, showed similar effects and adverse events compared to other antipsychotics in a review of randomized trials. Despite its long history, more research is needed due to data limitations.

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

5.0K
Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

14.8K

Related Experiment Videos

Last Updated: Apr 16, 2026

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
12:00

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

Published on: November 19, 2014

13.4K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

5.0K
Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

14.8K

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Trial Analysis

Background:

  • Perphenazine is a phenothiazine antipsychotic with potency comparable to haloperidol.
  • It has a long history of use, particularly in Northern European countries and Japan.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of perphenazine for schizophrenia and schizophrenia-like psychoses.
  • To synthesize evidence from randomized controlled trials comparing perphenazine with other treatments.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Searches updated through September 2013, including trial registers, references, and direct contact with pharmaceutical companies and authors.
  • Exclusion of trials involving depot formulations of perphenazine; data extraction and quality assessment performed independently by two reviewers.

Main Results:

  • Thirty-one RCTs with 4662 participants were included.
  • Compared to placebo, perphenazine showed a significant benefit in clinical response (very low quality evidence).
  • No significant differences in clinical effects or adverse events (including dystonia and serious adverse events) were found when comparing perphenazine with other antipsychotic drugs (very low quality evidence).

Conclusions:

  • Incomplete reporting and diverse comparators limit definitive conclusions about perphenazine's efficacy and safety.
  • Current evidence suggests perphenazine has comparable effects and adverse event profiles to other antipsychotics.
  • Further high-quality randomized trials are warranted to fully elucidate the properties of this established antipsychotic.